Eloxx Pharmaceuticals Current Ratio vs. EBITDA

ELOXDelisted Stock  USD 6.12  0.30  4.67%   
Based on Eloxx Pharmaceuticals' profitability indicators, Eloxx Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Eloxx Pharmaceuticals' ability to earn profits and add value for shareholders.
For Eloxx Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Eloxx Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Eloxx Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Eloxx Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Eloxx Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
Please note, there is a significant difference between Eloxx Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eloxx Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eloxx Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Eloxx Pharmaceuticals EBITDA vs. Current Ratio Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Eloxx Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Eloxx Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Eloxx Pharmaceuticals is rated below average in current ratio category among its peers. It also is rated below average in ebitda category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Eloxx Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Eloxx Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Eloxx EBITDA vs. Current Ratio

Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Eloxx Pharmaceuticals

Current Ratio

 = 

Current Asset

Current Liabilities

 = 
1.62 X
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Eloxx Pharmaceuticals

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(34.42 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Eloxx EBITDA Comparison

Eloxx Pharmaceuticals is currently under evaluation in ebitda category among its peers.

Eloxx Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Eloxx Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Eloxx Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Eloxx Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Eloxx Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts. Eloxx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.

Eloxx Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Eloxx Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Eloxx Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Eloxx Pharmaceuticals' important profitability drivers and their relationship over time.

Use Eloxx Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eloxx Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eloxx Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Eloxx Pharmaceuticals Pair Trading

Eloxx Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Eloxx Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eloxx Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eloxx Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eloxx Pharmaceuticals to buy it.
The correlation of Eloxx Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eloxx Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eloxx Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eloxx Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Eloxx Pharmaceuticals position

In addition to having Eloxx Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Convertibles Funds Thematic Idea Now

Convertibles Funds
Convertibles Funds Theme
Funds or Etfs that invest in debt that is expected to be converted into a predetermined amount of the company equity at some future date. The Convertibles Funds theme has 12 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Convertibles Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Eloxx Pink Sheet

If you are still planning to invest in Eloxx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eloxx Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Stocks Directory
Find actively traded stocks across global markets
Money Managers
Screen money managers from public funds and ETFs managed around the world
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.